Ractigen doses first subject in Phase I ALS treatment trial
Ractigen Therapeutics has dosed the first subject in the randomised Phase I clinical trial of its small interfering RNA (siRNA)…
All articles by
-
-
Zura Bio initiates Phase II systemic sclerosis treatment trial
Zura Bio has initiated the double-blind Phase II TibuSURE trial to assess the humanised tetravalent bispecific dual-antagonist antibody, tibulizumab, in…
-
GSK’s combo therapy trial for advanced ovarian cancer meets primary endpoint
GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) and Jemperli (dostarlimab) combination in treating…
-
Alumis reports positive outcomes from Phase I trial of TYK2 inhibitor
Alumis has revealed encouraging results from a Phase I clinical trial of a selective tyrosine kinase 2 (TYK2) inhibitor, A-005,…
-
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy
US-based biotechnology company Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma…
-
MSD’s DOR/ISL regimen meets primary efficacy hypotheses in HIV-1 treatment trials
US-based pharmaceutical company MSD has reported positive results from two Phase III trials of doravirine/islatravir (DOR/ISL), an oral treatment regimen…
-
Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial
Sarepta Therapeutics has completed enrolment and dosing in the global Phase III EMERGENE trial of its investigational gene therapy, SRP-9003…
-
Remedy Plan commences dosing in Phase I cancer therapy trial
Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, RPT1G, for cancers.…
-
Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial
Precision BioSciences has gained the approval of its clinical trial application (CTA) in Hong Kong to study PBGENE-HBV, a gene…
-
Immunocore doses first subject in gastrointestinal cancer therapy trial
Immunocore Holdings has dosed the first subject in a multicentre Phase I/II trial of IMC-R117C, a PIWIL1-targeted immunotherapy, for treating…